Chemical Compound

Notoginsenoside Ft1

CAS Registry Number 155683-00-4
Notoginsenoside Ft1 chemical structure
Primary Record

Notoginsenoside Ft1

Note: Only for scientific research or as raw materials for production.

In stock
792 g
Purity
99.8 %
CAS
155683-00-4

Compound Identifiers & Properties

CAS
155683-00-4
PubChem CID
91973814
SMILES
CC(=CCC[C@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)C)C)O)C)O)C
Canonical SMILES
CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4OC[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C

Names & Synonyms

  • Notoginsenoside Ft1
  • 155683-00-4
  • Notoginsenoside Ft1?
  • RefChem:166838
  • orb1301515
  • SCHEMBL29411783
  • MFCD22125013
  • DTXSID701350136
  • HY-N0910
  • 8189AH
  • C47H80O17
  • MSK184971
  • NP7041
  • AKOS037515008
  • ZINC253387908
  • ACN-047760
  • CS-4166
  • EBC-615564
  • DA-56275
  • MS-31713
  • FT-0772861
  • FT-0777248
  • J2.362.927E
  • A883632
  • 2(3H)-Furanone,5-(3-hexenyl)dihydro-,(R-(Z))-
  • beta-D-Glucopyranoside, (3beta,12beta,20R)-12,20-dihydroxydammar-24-en-3-yl O-beta-D-xylopyranosyl-(1-->2)-O-beta-D-glucopyranosyl-(1-->2)-
  • (2S,3R,4S,5R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
  • (2S,3R,4S,5R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3
  • (2S,3R,4S,5R)-2-{[(2S,3R,4S,5S,6R)-2-{[(2R,3R,4S,5S,6R)-2-{[(1S,3aR,3bR,5aR,7S,9aR,9bR,11R,11aR)-11-hydroxy-1-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}oxane-3,4,5-triol
  • (2S,3R,4S,5R)-2-((2S,3R,4S,5S,6R)-2-((2R,3R,4S,5S,6R)-4,5-dihydroxy-2-(((3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-((2R)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta(a)phenanthren-3-yl)oxy)-6-(hydroxymethyl)oxan-3-yl)oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxyoxane-3,4,5-triol
  • (2S,3R,4S,5R)-2-{[(2S,3R,4S,5S,6R)-2-{[(2R,3R,4S,5S,6R)-2-{[(1S,3AR,3BR,5AR,7S,9AR,9BR,11R,11AR)-11-HYDROXY-1-[(2R)-2-HYDROXY-6-METHYLHEPT-5-EN-2-YL]-3A,3B,6,6,9A-PENTAMETHYL-DODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-7-YL]OXY}-4,5-DIHYDROXY-6-(HYDROXYMETHYL)OXAN-3-YL]OXY}-4,5-DIHYDROXY-6-(HYDROXYMETHYL)OXAN-3-YL]OXY}OXANE-3,4,5-TRIOL
  • [(20R)-12beta,20-Dihydroxydammarane-24-ene-3beta-yl]2-O-[2-O-(beta-D-xylopyranosyl)-beta-D-glucopyranosyl]-beta-D-glucopyranoside
  • |A-D-Glucopyranoside, (3|A,12|A,20R)-12,20-dihydroxydammar-24-en-3-yl O-|A-D-xylopyranosyl-(1 inverted exclamation marku2)-O-|A-D-glucopyranosyl-(1 inverted exclamation marku2)-
  • beta-D-Glucopyranoside, (3beta,12beta,20R)-12,20-dihydroxydammar-24-en-3-yl O-beta-D-xylopyranosyl-(12)-O-beta-D-glucopyranosyl-(12)-